Document ID: chunk:federal_register_of_legislation:F2022C00579:front:0:p6
Version: federal_register_of_legislation:F2022C00579
Segment Type: other
Provision Reference: 
Character Range: 14329–17345

of hypogonadism;
(43)      having infarction of:
(a)          both ovaries or testes; or
(b)          a single functional ovary or testis, where there is only one functional ovary or testis;
within the 1 year before the clinical worsening of hypogonadism;
(44)      having sickle-cell disorder before the clinical worsening of hypogonadism;
(45)      having a bone marrow or stem cell transplant before the clinical worsening of hypogonadism;
(46)      having cirrhosis of the liver at time of the clinical worsening of hypogonadism;
(47)      having chronic kidney disease at time of the clinical worsening of hypogonadism;
            Note: chronic kidney disease is defined in the Schedule 1 - Dictionary.
(48)      having anorexia nervosa at the time of the clinical worsening of hypogonadism;
(49)      taking a course of systemic cytotoxic drugs for treatment of a malignant neoplasm before the clinical worsening of hypogonadism;
(50)      taking gonadotrophin releasing hormone agonists or antagonists as androgen or estrogen deprivation therapy for at least 1 year within the 2 years before the clinical worsening of hypogonadism;
(51)      having active epilepsy before the clinical worsening of hypogonadism;
            Note: active epilepsy is defined in the Schedule 1 - Dictionary.
(52)      taking a drug from the Specified List 1 of drugs before the clinical worsening of hypogonadism;
            Note: Specified List 1 of drugs is defined in the Schedule 1 - Dictionary.
(53)      taking an immune checkpoint inhibitor within the 1 year before the clinical worsening of hypogonadism;
            Note: immune checkpoint inhibitor is defined in the Schedule 1 - Dictionary.
(54)      taking a drug from the Specified List 2 of drugs, which cannot be ceased or substituted, at the time of the clinical worsening of hypogonadism;
            Note: Specified List 2 of drugs is defined in the Schedule 1 - Dictionary.
(55)      taking a drug which cannot be ceased or substituted and which is associated in the individual with the clinical worsening of hypogonadism during drug therapy and either:
(a)          the improvement of hypogonadism within 2 months of discontinuing or tapering drug therapy; or
(b)          the clinical worsening of hypogonadism on rechallenge with the same drug; and
where taking the drug continued for at least the 30 days before the clinical worsening of hypogonadism;
(56)      inhaling fumes from a metal from the specified list of metals or a compound containing a metal from the specified list of metals:
(a)          for a cumulative period of at least 2,000 hours before the clinical worsening of hypogonadism; and
(b)          if that exposure has ceased before the clinical worsening of hypogonadism, then that worsening occurred within 2 years of cessation;
            Note: fumes and specified list of metals are defined in the Schedule 1 - Dictionary.
(57)      inhaling, ingesting or having cutaneous contact with a chemical agent from the specified list of